Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
- Prat, Alexandre
- Kalincik, Tomas
- Havrdova, Eva Kubala
- Horakova, Dana
- Izquierdo, Guillermo
- Girard, Marc
- Duquette, Pierre
- Grammond, Pierre
- Onofrj, Marco
- Lugaresi, Alessandra
- Kappos, Ludwig
- Grand'Maison, Francois
- Prevost, Julie
- Sola, Patrizia
- Ferraro, Diana
- Granella, Franco
- Trojano, Maria
- Bergamaschi, Roberto
- Pucci, Eugenio
- Turkoglu, Recai
- McCombe, Pamela A.
- Van Pesch, Vincent
- Van Wijmeersch, Bart
- Solaro, Claudio
- KARABUDAK, RANA
- Butler, Ernest
- Vucic, Steve
- Jokubaitis, Vilija
- Spelman, Tim
- Butzkueven, Helmut
- Kuhle, Jens
- TERZİ, MURAT
- Lechner-Scott, Jeannette
- BOZ, CAVİT
- Ramo-Tello, Cristina
- Slee, Mark
- Alroughani, Raed
- Yamout, Bassem
- Shaygannejad, Vahid
- Spitaleri, Daniele
- Luis Sanchez-Menoyo, Jose
- Ampapa, Radek
- Hodgkinson, Suzanne
- ÖZAKBAŞ, SERKAN
Publication date
April 2019
DOIAbstract
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed
Add to ORKG